LongoVital in the prevention of recurrent aphthous ulceration

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

LongoVital in the prevention of recurrent aphthous ulceration. / Pedersen, A; Hougen, H P; Klausen, B; Winther, K.

In: Journal of Oral Pathology & Medicine, Vol. 19, No. 8, 1990, p. 371-5.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Pedersen, A, Hougen, HP, Klausen, B & Winther, K 1990, 'LongoVital in the prevention of recurrent aphthous ulceration', Journal of Oral Pathology & Medicine, vol. 19, no. 8, pp. 371-5.

APA

Pedersen, A., Hougen, H. P., Klausen, B., & Winther, K. (1990). LongoVital in the prevention of recurrent aphthous ulceration. Journal of Oral Pathology & Medicine, 19(8), 371-5.

Vancouver

Pedersen A, Hougen HP, Klausen B, Winther K. LongoVital in the prevention of recurrent aphthous ulceration. Journal of Oral Pathology & Medicine. 1990;19(8):371-5.

Author

Pedersen, A ; Hougen, H P ; Klausen, B ; Winther, K. / LongoVital in the prevention of recurrent aphthous ulceration. In: Journal of Oral Pathology & Medicine. 1990 ; Vol. 19, No. 8. pp. 371-5.

Bibtex

@article{e8a5c1000d544b28a21d39821ab85072,
title = "LongoVital in the prevention of recurrent aphthous ulceration",
abstract = "LongoVital (LV) (DK. Reg. No. 5178/75) is a herbal based tablet enriched with recommended doses of vitamins. The present study was undertaken to investigate prevention of recurrent aphthous ulceration (RAU) during 6 months' daily intake of LV as compared with placebo in a double-blind, randomized clinical, cross-over 1-yr study. The population comprised 29 otherwise healthy minor RAU patients (18 F, 11 M), mean age 36 (18-67), with an estimated average number of recurrences the previous year of 12.8 (3-30). The number of recurrences was significantly reduced on LV the latter 4 of the 6 months (P less than 0.01) where 31% were totally free of recurrences. Subjective all-over evaluation of treatment period was significantly in favor of LV. LV induced no adverse reactions and is the first harmless systemic treatment which has proved better than placebo in the prevention of RAU.",
keywords = "Adolescent, Adult, Aged, Binomial Distribution, Double-Blind Method, Female, Humans, Male, Middle Aged, Phytotherapy, Prospective Studies, Recurrence, Stomatitis, Aphthous, Ulcer, Vitamins",
author = "A Pedersen and Hougen, {H P} and B Klausen and K Winther",
year = "1990",
language = "English",
volume = "19",
pages = "371--5",
journal = "Journal of Oral Pathology and Medicine",
issn = "0904-2512",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - LongoVital in the prevention of recurrent aphthous ulceration

AU - Pedersen, A

AU - Hougen, H P

AU - Klausen, B

AU - Winther, K

PY - 1990

Y1 - 1990

N2 - LongoVital (LV) (DK. Reg. No. 5178/75) is a herbal based tablet enriched with recommended doses of vitamins. The present study was undertaken to investigate prevention of recurrent aphthous ulceration (RAU) during 6 months' daily intake of LV as compared with placebo in a double-blind, randomized clinical, cross-over 1-yr study. The population comprised 29 otherwise healthy minor RAU patients (18 F, 11 M), mean age 36 (18-67), with an estimated average number of recurrences the previous year of 12.8 (3-30). The number of recurrences was significantly reduced on LV the latter 4 of the 6 months (P less than 0.01) where 31% were totally free of recurrences. Subjective all-over evaluation of treatment period was significantly in favor of LV. LV induced no adverse reactions and is the first harmless systemic treatment which has proved better than placebo in the prevention of RAU.

AB - LongoVital (LV) (DK. Reg. No. 5178/75) is a herbal based tablet enriched with recommended doses of vitamins. The present study was undertaken to investigate prevention of recurrent aphthous ulceration (RAU) during 6 months' daily intake of LV as compared with placebo in a double-blind, randomized clinical, cross-over 1-yr study. The population comprised 29 otherwise healthy minor RAU patients (18 F, 11 M), mean age 36 (18-67), with an estimated average number of recurrences the previous year of 12.8 (3-30). The number of recurrences was significantly reduced on LV the latter 4 of the 6 months (P less than 0.01) where 31% were totally free of recurrences. Subjective all-over evaluation of treatment period was significantly in favor of LV. LV induced no adverse reactions and is the first harmless systemic treatment which has proved better than placebo in the prevention of RAU.

KW - Adolescent

KW - Adult

KW - Aged

KW - Binomial Distribution

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Phytotherapy

KW - Prospective Studies

KW - Recurrence

KW - Stomatitis, Aphthous

KW - Ulcer

KW - Vitamins

M3 - Journal article

C2 - 2250227

VL - 19

SP - 371

EP - 375

JO - Journal of Oral Pathology and Medicine

JF - Journal of Oral Pathology and Medicine

SN - 0904-2512

IS - 8

ER -

ID: 44355105